First Drug Approved for Ultra-Rare Kidney Disease

(MedPage Today) — The FDA approved iptacopan (Fabhalta) as the first treatment to reduce proteinuria in adults with complement 3 glomerulopathy (C3G), the agency announced Thursday.
“C3G is a debilitating disease often affecting young people…